These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 34607253)

  • 1. Melatonin in neuroskeletal biology.
    Patel A; Zhou EW; O'Brien M; Wang X; Zhou S
    Curr Opin Pharmacol; 2021 Dec; 61():42-48. PubMed ID: 34607253
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The multiple protective roles and molecular mechanisms of melatonin and its precursor N-acetylserotonin in targeting brain injury and liver damage and in maintaining bone health.
    Luo C; Yang Q; Liu Y; Zhou S; Jiang J; Reiter RJ; Bhattacharya P; Cui Y; Yang H; Ma H; Yao J; Lawler SE; Zhang X; Fu J; Rozental R; Aly H; Johnson MD; Chiocca EA; Wang X
    Free Radic Biol Med; 2019 Jan; 130():215-233. PubMed ID: 30315933
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Regulation of bone mass through pineal-derived melatonin-MT2 receptor pathway.
    Sharan K; Lewis K; Furukawa T; Yadav VK
    J Pineal Res; 2017 Sep; 63(2):. PubMed ID: 28512916
    [TBL] [Abstract][Full Text] [Related]  

  • 4. MT1 and MT2 melatonin receptors: ligands, models, oligomers, and therapeutic potential.
    Zlotos DP; Jockers R; Cecon E; Rivara S; Witt-Enderby PA
    J Med Chem; 2014 Apr; 57(8):3161-85. PubMed ID: 24228714
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Melatonin exerts by an autocrine loop antiproliferative effects in cholangiocarcinoma: its synthesis is reduced favoring cholangiocarcinoma growth.
    Han Y; Demorrow S; Invernizzi P; Jing Q; Glaser S; Renzi A; Meng F; Venter J; Bernuzzi F; White M; Francis H; Lleo A; Marzioni M; Onori P; Alvaro D; Torzilli G; Gaudio E; Alpini G
    Am J Physiol Gastrointest Liver Physiol; 2011 Oct; 301(4):G623-33. PubMed ID: 21778461
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Melatonin inhibits cholangiocyte hyperplasia in cholestatic rats by interaction with MT1 but not MT2 melatonin receptors.
    Renzi A; Glaser S; Demorrow S; Mancinelli R; Meng F; Franchitto A; Venter J; White M; Francis H; Han Y; Alvaro D; Gaudio E; Carpino G; Ueno Y; Onori P; Alpini G
    Am J Physiol Gastrointest Liver Physiol; 2011 Oct; 301(4):G634-43. PubMed ID: 21757639
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pineal and cortical melatonin receptors MT1 and MT2 are decreased in Alzheimer's disease.
    Brunner P; Sözer-Topcular N; Jockers R; Ravid R; Angeloni D; Fraschini F; Eckert A; Müller-Spahn F; Savaskan E
    Eur J Histochem; 2006; 50(4):311-6. PubMed ID: 17213040
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Alterations of melatonin receptors MT1 and MT2 in the hypothalamic suprachiasmatic nucleus during depression.
    Wu YH; Ursinus J; Zhou JN; Scheer FA; Ai-Min B; Jockers R; van Heerikhuize J; Swaab DF
    J Affect Disord; 2013 Jun; 148(2-3):357-67. PubMed ID: 23357659
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Activation of melatonin receptor 2 but not melatonin receptor 1 mediates melatonin-conferred cardioprotection against myocardial ischemia/reperfusion injury.
    Han D; Wang Y; Chen J; Zhang J; Yu P; Zhang R; Li S; Tao B; Wang Y; Qiu Y; Xu M; Gao E; Cao F
    J Pineal Res; 2019 Aug; 67(1):e12571. PubMed ID: 30903623
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Melatonin MT
    López-Canul M; Min SH; Posa L; De Gregorio D; Bedini A; Spadoni G; Gobbi G; Comai S
    Int J Mol Sci; 2019 May; 20(10):. PubMed ID: 31108968
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Melatonin Signaling Controls the Daily Rhythm in Blood Glucose Levels Independent of Peripheral Clocks.
    Owino S; Contreras-Alcantara S; Baba K; Tosini G
    PLoS One; 2016; 11(1):e0148214. PubMed ID: 26824606
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Perioperative melatonin use.
    Jarratt J
    Anaesth Intensive Care; 2011 Mar; 39(2):171-81. PubMed ID: 21485664
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Decreased MT1 and MT2 melatonin receptor expression in extrapineal tissues of the rat during physiological aging.
    Sánchez-Hidalgo M; Guerrero Montávez JM; Carrascosa-Salmoral Mdel P; Naranjo Gutierrez Mdel C; Lardone PJ; de la Lastra Romero CA
    J Pineal Res; 2009 Jan; 46(1):29-35. PubMed ID: 18513209
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Is postmenopausal osteoporosis related to pineal gland functions?
    Sandyk R; Anastasiadis PG; Anninos PA; Tsagas N
    Int J Neurosci; 1992 Feb; 62(3-4):215-25. PubMed ID: 1305608
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evidence that membrane-bound G protein-coupled melatonin receptors MT1 and MT2 are not involved in the neuroprotective effects of melatonin in focal cerebral ischemia.
    Kilic U; Yilmaz B; Ugur M; Yüksel A; Reiter RJ; Hermann DM; Kilic E
    J Pineal Res; 2012 Mar; 52(2):228-35. PubMed ID: 21913972
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Sites and mechanisms of action of melatonin in mammals: the MT1 and MT2 receptors].
    Schuster C
    J Soc Biol; 2007; 201(1):85-96. PubMed ID: 17762828
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sleep well. Untangling the role of melatonin MT1 and MT2 receptors in sleep.
    Gobbi G; Comai S
    J Pineal Res; 2019 Apr; 66(3):e12544. PubMed ID: 30586215
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The influence od melatonin receptors antagonists, luzindole and 4-phenyl-2-propionamidotetralin (4-P-PDOT), on melatonin-dependent vasopressin and adrenocorticotropic hormone (ACTH) release from the rat hypothalamo-hypophysial system. In vitro and in vivo studies.
    Juszczak M; Roszczyk M; Kowalczyk E; Stempniak B
    J Physiol Pharmacol; 2014 Dec; 65(6):777-84. PubMed ID: 25554981
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Melatonin: Another avenue for treating osteoporosis?
    Li T; Jiang S; Lu C; Yang W; Yang Z; Hu W; Xin Z; Yang Y
    J Pineal Res; 2019 Mar; 66(2):e12548. PubMed ID: 30597617
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ramelteon, a selective MT1/MT2 receptor agonist, suppresses the proliferation and invasiveness of endometrial cancer cells.
    Osanai K; Kobayashi Y; Otsu M; Izawa T; Sakai K; Iwashita M
    Hum Cell; 2017 Jul; 30(3):209-215. PubMed ID: 28382516
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.